PRESS RELEASE published on 12/29/2025 at 08:00, 8 months 19 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 8 months 26 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 8 months 26 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
PRESS RELEASE published on 12/22/2025 at 07:00, 8 months 26 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 10 months 3 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 10 months 18 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 11 months 17 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 11 months 17 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 11 months 17 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 1 year ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
Published on 09/17/2026 at 14:50, 14 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 14:47, 17 minutes ago Nextech3D.ai Announces CEO Evan Gappelberg Acquires 7.4 Million Shares
Published on 09/17/2026 at 14:31, 33 minutes ago First Breach Announces Three-Year Ammunition Supply and Distribution Agreement with SAS Ammo
Published on 09/17/2026 at 13:30, 1 hour 34 minutes ago UniDoc Health Equips San Juan, Puerto Rico Ambulances With Live Patient Video
Published on 09/17/2026 at 13:30, 1 hour 34 minutes ago Electric Royalties Reports Permitting Progress and New Exploration Results Across Critical Metals Royalty Portfolio
Published on 09/17/2026 at 14:35, 29 minutes ago Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $380 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens
Published on 09/17/2026 at 14:30, 34 minutes ago Hong Kong sets out strategic vision for developing the Northern Metropolis and creating a global talent hub
Published on 09/17/2026 at 13:25, 1 hour 38 minutes ago Custodian Property Income REIT plc: Results of Annual General Meeting
Published on 09/17/2026 at 13:25, 1 hour 39 minutes ago CDTL Highlights E-Drive + EMB Technologies for Commercial Vehicles at IAA Transportation 2026
Published on 09/17/2026 at 13:25, 1 hour 39 minutes ago ATOME PLC: Notice of Dispute and Intent to Submit Claim to Arbitration under the UK - Paraguay Bilateral Investment Treaty ("the Treaty" or "BIT")
Published on 09/16/2026 at 17:45, 21 hours 19 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 8 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 21 hours ago Report on the Combined General Meeting of the 10th of September 2026
